“I just received the copy of Oncology & Hematology Review in the mail – it looks great!”
Endometrial carcinoma is the most common malignancy of the female genital tract, accounting for more than 42,000 cases annually in the US (6% of new cancer cases).1 Worldwide, it is the seventh most common cancer in women, with over 200,000 cases annually.2 Fortunately, most women present with dysfunctional vaginal bleeding or spotting—an early sign of endometrial pathology—and ultimately will be cured with surgical therapy. Unfortunately, more than 7,500 die of advanced or recurrent endometrial carcinoma every year.1 Endometrial carcinomas are classified as type I or type II.3,4 Type I tumors evolve in an estrogenrelated manner, are associated with endometrial hyperplasia, and express steroid hormone receptors. The usual pathologic phenotype is an endometrioid adenocarcinoma, which tends to be well differentiated and of low grade. By contrast, type II tumors—classically characterized as serous or clear-cell carcinomas—arise in atrophic endometrium in a manner unrelated to estrogen exposure. These tumors are usually negative or weakly positive for steroid hormone receptors, and are typically poorly differentiated and of high grade. In general, type II tumors are characterized by a more aggressive clinical course than type I tumors.3
The current treatment of endometrial carcinomas requires multimodal therapy and depends on the stage at presentation, histologic grade, and type. Surgery alone or with radiation therapy, chemotherapy, or endocrine therapy are all utilized in the front-line management of this disease. For women presenting with high-risk features (serous or clear cell, grade 3, deeply invasive to the myometrium, and nodal involvement), a combination of surgical staging followed by chemotherapy with or without radiation therapy is often employed.